Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SMCRH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
jP2025004232A ADC3 7.31
|
|||||
| Synonyms |
ADC3
Click to Show/Hide
|
|||||
| Organization |
Sumitomo Pharma Co., Ltd
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.31
|
|||||
| Structure |
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
M2
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.019 nM
|
|||
| Method Description |
The Karpas-299 cells (ECACC), which express CD30 antigen and are negative for HER2 antigen, were cultured to reach 2×106 cells/mL. 50 uL of each was added to 96-well cell culture microplates. 50 uL of CellTiter-Glo Luminescent Cell Viability Assay (Promega) was added to each well and mixed. The mixture was incubated in the dark for 20 minutes. The luminescence was measured using a microplate illuminometer, and the cell survival rates at each ADC concentration were calculated accordingly.The IC50 value can be calculated based on the value of cell survival rate.
Click to Show/Hide
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||